Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers, Exosomes & Liquid Biopsy Asia 2019

Circulating Biomarkers, Exosomes & Liquid Biopsy Asia 2019 Agenda


Print Agenda

Monday, 9 September 2019

00:00

Inhibition of Exosome Secretion in Cancer Cells by an Antibiotic
Moon-Chang Baek, Director, Exosome Convergence Research Center (ECRC), Kyungpook National University School of Medicine, Korea South

Inhibitors of the secretion of cancer exosomes, which promote cancer progression and metastasis, may not only accelerate exosome biology research but also offer therapeutic benefits for cancer patients. We identify sulfisoxazole (SFX) as an inhibitor of small extracellular vesicles (sEV) secretion from breast cancer cells through interference with endothelin receptor A (ETA). SFX, an FDA-approved oral antibiotic, showed significant anti-tumor and anti-metastatic effects in mouse models of breast cancer xenografts, reduced the expression of proteins involved in biogenesis and secretion of sEV, and triggered co-localization of multivesicular endosomes with lysosomes for degradation. The important role of ETA, as a newly-identified target of SFX, is demonstrated by gain- and loss-of-function studies of ETA protein through a direct binding assay, pharmacological and genetic approaches. These findings may provide a foundation for sEV-targeted cancer therapies and the mechanistic studies on sEV biology.

00:00

Title to be Confirmed.
Kihwan Kwon, Professor, Ewha Womans University College of Medicine, Korea South

00:00

Sai Kiang LimKeynote Presentation

Title to be Confirmed.
Sai Kiang Lim, Research Director, Institute of Medical Biology, A*STAR, Singapore

00:00

Yong Song GhoConference Chair

Title to be Confirmed.
Yong Song Gho, Professor, Pohang University Of Science And Technology South Korea, Korea South

00:00

Chulhee ChoiConference Chair

Title to be Confirmed.
Chulhee Choi, Professor and Chair, BioMedical Imaging Center, Korea Advanced Institute of Science and Technology (KAIST), President, Cellex Life Sciences, Korea South

00:00

Dominique PV de KleijnKeynote Presentation

Title to be Confirmed.
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands

00:00

Steve SoperKeynote Presentation

Title to be Confirmed.
Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology, United States of America

00:00

Sehyun ShinKeynote Presentation

Title to be Confirmed.
Sehyun Shin, Professor & Director, Nano-Biofluignostic Engineering Research Center, Korea University and Anam/Guro Hospital of Korea University, Korea South

00:00

Chwee Teck LimKeynote Presentation

Title to be Confirmed.
Chwee Teck Lim, NUS Society Chair Professor, Acting Director, Biomedical Institute for Global Health Research and Technology, National University of Singapore, Singapore

00:00

Hyo-Il JungKeynote Presentation

Title to be Confirmed.
Hyo-Il Jung, Professor, Yonsei University, Korea South

00:00

Yoon-Kyoung ChoKeynote Presentation

Title to be Confirmed.
Yoon-Kyoung Cho, Professor, Biomedical Engineering, Ulsan National Institute of Science & Technology; Group leader, IBS; FRSC, Fellow of Royal Society of Chemistry, Korea South

00:00

Jan LötvallKeynote Presentation

Title to be Confirmed.
Jan Lötvall, Professor, University of Gothenburg; Founding President of ISEV, Sweden

00:00

Andreas MöllerKeynote Presentation

Protein Content of Extracellular Vesicles as Biomarker in Cancer
Andreas Möller, Associate Professor, QIMR Berghofer Medical Research Institute, Australia

Despite significant therapeutic advances, cancer remains a leading cause of death worldwide. A significant clinical problem is the generally late discovery of a cancer and the uncertainty of choosing the most effective therapy for the individual patient. Several novel biomarkers are proposed, ranging from genetic and genomic evaluations of the cancer or the cancer material in circulation to assessing nucleic acids, proteins or lipids. Accurate cancer biomarkers, in particular non-invasive liquid biomarkers based on blood samples or other body fluids, will allow clinicians to identify cancer patients early, triage them to the most appropriate intervention and follow the response of the cancer in real time over the course of the therapy.

In this presentation, I will share data on a novel biomarker for Non-Small-Cell Lung Cancer (NSCLC). We have developed a blood-based multi-protein signature capable of accurately prognosticating clinical outcome in NSCLC patient cohorts. This signature is contained in small circulating nano-vesicles termed exosomes. Overall, this work describes a novel prognostic biomarker signature to identify early stage NSCLC patients at risk of developing metastatic NSCLC, thereby enabling implementation of personalized adjuvant treatment decisions.


Agenda is not currently available
Add to Calendar ▼2019-09-09 00:00:002019-09-10 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com